Codexis Inc is a biotechnology company that focuses on the development and application of protein engineering technologies to create innovative solutions for various industries, including pharmaceuticals, biotechnology, and agriculture. The company leverages its proprietary CodeEvolver platform to design and optimize enzymes for improved performance and efficiency, facilitating the production of active pharmaceutical ingredients and other bio-based products. With a strong emphasis on sustainability and reducing environmental impact, Codexis aims to transform traditional manufacturing processes through its engineered proteins, thereby advancing the future of bioeconomy and contributing to healthier living. Read More
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (Nasdaq: CDXS), a leading enzyme engineering company, and was the former CTO of Allogene Therapeutics (Nasdaq: ALLO), a pioneering clinical-stage company advancing CAR T-cell therapies.
Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI).
